The BCG dilemma: linear versus non-linear correlation models over the time of the COVID-

19 pandemic

Guillermo Lopez-Campos^{1*}, PhD; Christopher Hawthorne¹, MSc; and Miguel A. Valvano¹, MD

¹Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, 97

Lisburn road, Belfast, United Kingdom BT9 7BL

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

In this work we have analysed the use of two different correlation metrics and two different datasets, detecting differences in the extent and directionality of the correlation between COVID-19 infection and BCG immunization. Correlation between COVID-19 infection, death rates and BCG immunization is strongly affected by the correlation metrics and so will be their biological interpretation.

Introduction:

BCG immunization has been suggested to have a protective role for COVID-19 since, due to its immunomodulatory properties, it would appear to reduce the severity of other viral infections¹. This was supported by several different analytical approaches and datasets analyzing the relationship between BCG vaccination rates around the world, COVID-19 cases and death rates²⁻⁴. Previous correlation analyses highlighted a negative correlation between BCG immunization and COVID-19, providing impetus for randomized clinical trials to evaluate if the BCG vaccine can reduce the severity of COVID-19⁵.

We have applied two different correlation methods (Spearman's and Pearson's) using the package psych in R, fortnightly COVID-19 infection and mortality rates between 15th January and 15th May 2020 (https://www.ecdc.europa.eu/en/publications-data/downloadtodays-data-geographic-distribution-covid-19-cases-worldwide), and two different BCG immunization datasets extracted from the WHO between 1980 and 2018 for one year old (1yo) children and undefined age immunization rates (https://www.who.int/data/maternalnewborn-child-adolescent/indicator-explorer-new/mca/baccille-calmette-gu%C3%A9rin-(bcg)-immunization-coverage-among-1-year-olds-(-) and https://www.who.int/immunization/monitoring_surveillance/data/en/).

The results show that in 1 year old children a negligible (or weakly positive) correlation between BCG immunization rates and COVID-19 death or case rates (15th May 2020) using Spearman's correlation. Whereas the opposite is observed using Pearson's correlation with a statistically significant weak to moderate negative correlation. Spearman's correlation allows the identification of monotonic trends compared to Pearson's linear correlation. The latter as well tends to fail in skewed distributions and is more sensitive to extreme values such as those observed in some non-vaccinated countries. Similar opposite results were observed when we used the alternative BCG immunization rates (Figure 1A).

We also analyzed fortnightly COVID-19 correlations during the pandemic and immunization rates in two different years (2000 and 2018). As before, Spearman's correlation data show a weak positive correlation over time (Figure 1C). However, correlation increased until mid-April when many countries started implementing different protective measures, it proceeded to declined slightly and seems to have stabilized in May.

The datasets used for these analyses lack some countries that either had BCG immunization policy at later ages, did not have them or it was discontinued or non-reported (E.g. UK, USA and Australia). To address this aspect, we included an oversimplified replacement of missing BCG coverage data with a 0% coverage. This replacement introduces important changes in the results obtained, inverting the previously discussed results showing a negative correlation between death rates and COVID-19 for both correlation metrics (Figure 1B and 1D).

This change also inverts the correlation between BCG immunization and tuberculosis incidence (Table 1). The inclusion of additional global variables highlighted aspects already observed in medical clinics, such as positive correlations between the percentage of the population with a BMI greater than 25 and COVID-19 death and case rates (Table 1).

4

Our analyses did not include any confounding factors that affect the evolution of the outbreak (e.g. implementation of social distancing measures, demographics or other social determinants of health).

Our results expose the limitations of using different analytical approaches and partial

datasets in the context of an ongoing outbreak, illustrating how data can be interpreted

very differently. Apart from any biological conclusions from our analytical approach

regarding the BCG immunization rate, these limitations should be considered before making

definitive associations based on correlations that may change over the time of an outbreak.

Acknowledgements:

This research was supported in part by the Biotechnology and Biological Sciences Research

Council (grant BB/S006281 to MAV & GLC)

References

1. Arts RJW, Moorlag S, Novakovic B, et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. *Cell Host Microbe* 2018; **23**(1): 89-100 e5.

2. Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? *EMBO Mol Med* 2020.


3. Macedo A, Febra C. Relation between BCG coverage rate and COVID-19 infection worldwide. *Med Hypotheses* 2020; **142**: 109816.

4. Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? *Allergy* 2020.

5. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. *Lancet* 2020; **395**(10236): 1545-6.

Figure 1. Correlation between BCG immunization rates and COVID-19 death and case rates.

In blue statistically significant correlations (p-value < 0.05)



Correlations between different COVID dates and BCG immunisation rates

Dataset	Correlation variables	Correlation method	Correlation value	p-value
	COVID-19 case rate and incidence	Spearman	0.57	1.4E-16
	of BMI > 25	Pearson	0.39	9.5E-8
	COVID-19 death rate and	Spearman	0.56	6.0E-16
	incidence of BMI > 25	Pearson	0.28	1.8E-4
	COVID-19 case rate and life	Spearman	0.70	4.1E-28
	expectancy in 2019	Pearson	0.48	8.3E-12
	COVID-19 death rate and life	Spearman	0.67	9.2E-25
	expectancy in 2019	Pearson	0.38	1.5E-7
1yo BCG	Immunization rate in 2000 vs	Spearman	-0.32	5.2E-5
immunization	Estimate incidence of			
rates without	Tuberculosis (per 100k people) in	Pearson	-0.10	0.20
replacement	2018			
1yo BCG	Immunization rate in 2000 vs	Spearman	0.19	7.7E-3
immunization	Estimate incidence of			
rates introducing	Tuberculosis (per 100k people) in	Pearson	0.22	2.2E-3
0% for NA data	2018			
General coverage	Immunization rate in 2000 vs	Spearman	-0.41	4.4E-7
without	Estimate incidence of			
replacement	Tuberculosis (per 100k people) in	Pearson	-0.38	3.2E-6
	2018			
General coverage	Immunization rate in 2000 vs	Spearman	0.19	7.7E-3
introducing 0%	Estimate incidence of	Dearcon	0.12	9.2E-2
for NA data	Tuberculosis (per 100k people) in	Pearson	0.12	9.2E-2
	2018			

Table 1. Correlations between other variables of interest.